Effect of a long-acting analogue of somatostatin, SMS 201-995, on the development of intestinal tumours in azoxymethane-treated rats.
The effect of daily parenteral administration of a long-acting analogue of somatostatin (SMS 201-995) on the development of intestinal tumours and the rate of crypt cell proliferation in azoxymethane-treated rats has been studied. SMS 201-995 had no significant effect on the number of colonic tumours induced. In the duodenum, SMS 201-995 administration was associated with a change in the number of tumours from 1.4/rat in saline-treated animals to 2.4/rat in animals treated for the last third of the study and 2.8/rat in animals treated with SMS for the entire duration of the study (P less than 0.02). SMS had no significant effect on the rate of cell proliferation in the duodenum, ileum or colon. The inhibition of release of gastrointestinal trophic hormones by this analogue of somatostatin thus does not appear to reduce the number of tumours in the intestine of azoxymethane-treated rats.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001397:Azoxymethane; D002455:Cell Division / Q000187:drug effects; D005755:Gastrins / Q000097:blood; D004763:Glucagon-Like Peptides / Q000097:blood; D007414:Intestinal Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D007422:Intestines / Q000187:drug effects; D008297:Male; D015282:Octreotide; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D005755:Gastrins; D013004:Somatostatin; D004763:Glucagon-Like Peptides; D001397:Azoxymethane; D015282:Octreotide